Helix Biomedix to focus on commercialisation, loses CSO
This article was originally published in Scrip
Executive Summary
Helix Biomedix of the US is shifting its focus from expanding its libraries of bioactive peptides and small molecules to "intensifying" efforts to commercialise them. As a result, the company's CSO Dr Timothy Falla is leaving his post.